≥99% HPLCPre-filled pen

AC-Selank + Delta Sleep (Blend)

Name: AC-Selank + Delta Sleep (Blend)
Brand: Dripfy
Availability: InStock

What it is?

This is an investigational blend of two neuropeptides: Selank, an anxiolytic heptapeptide derived from the immunopeptide tuftsin, and Delta Sleep-Inducing Peptide (DSIP), a nonapeptide historically linked to slow-wave sleep. Neither component is approved in the EU/UK, and the combination is used only under physician direction.

Dripfy Advantage

Anxiolytic signalling: Selank is studied for modulation of GABAergic and monoaminergic pathways linked to stress and anxiety.
Neurotrophic pathways: Selank is associated in research with brain-derived neurotrophic factor (BDNF) and enkephalin signalling.
Sleep-architecture research: DSIP is investigated for its influence on slow-wave sleep and sleep-onset dynamics.
Stress-axis modulation: DSIP is examined in early work for stress-hormone signalling.
Combined framing: The blend overlays calm- and sleep-related signalling, though the interaction is not well characterised in humans.

Research & Investigational Focus

Anxiety modulation: Investigated for stress-response and anxiety-related signalling (Selank component).
Sleep support: Studied for influence on sleep onset and sleep architecture (DSIP component).
Stress-hormone signalling: Explored in early research for cortisol-axis modulation.
Combined calm/sleep frameworks: Positioned for physician-directed research combining both pathways.

Composition & Formulation

Format: Pre-filled pen
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€499

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

AC-Selank + Delta Sleep (Blend)

Investigational anxiolytic/sleep peptide blend (Selank + DSIP) · Pre-filled pen

D· Preliminary evidence

This blend combines two investigational neuropeptides. Selank is a synthetic heptapeptide derived from the immunopeptide tuftsin, studied for anxiolytic effects and for modulation of GABAergic and monoaminergic signalling as well as BDNF and enkephalin pathways. DSIP is a nonapeptide first isolated in association with slow-wave sleep and investigated for its influence on sleep architecture and stress-hormone regulation, though its endogenous role remains incompletely defined. Combining the two is intended to overlay calm- and sleep-related signalling, but the interaction has not been characterised in controlled human studies.

Studied use areas

Investigated for stress-response and anxiety-related signalling (Selank component)
Studied for influence on sleep onset and sleep architecture (DSIP component)
Explored in early research for cortisol-axis / stress-hormone signalling
Positioned for physician-directed research combining calm and sleep pathways

Safety & status

Investigational blend; neither component is EU/UK-approved and combined human safety and efficacy data are very limited
Combining two compounds compounds the uncertainty — interactions and additive effects are poorly characterised, so physician supervision is mandatory
Not for use in pregnancy or breastfeeding, or alongside sedatives or CNS depressants without physician oversight

⚕ Clinical note: This is educational information, not medical advice. This Selank + DSIP blend is investigational and unapproved in the EU/UK, and combining compounds increases the uncertainty; it is intended for physician-directed use only and is not a treatment for anxiety, insomnia, or any condition.

Evidence: Grade D — investigational; limited human data, mainly preclinical · References: Zozulya AA et al., Bulletin of Experimental Biology and Medicine, 2008; Graf MV, Kastin AJ, Neuroscience & Biobehavioral Reviews, 1986; Kozlovskaya MM et al., Neuroscience and Behavioral Physiology, 2003